|Table of Contents|

Construction of a column line graph prediction model of poor postoperative prognosis in patients with non-small cell lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 10
Page:
1820-1824
Research Field:
Publishing date:

Info

Title:
Construction of a column line graph prediction model of poor postoperative prognosis in patients with non-small cell lung cancer
Author(s):
GUO Jiajia; GAO Yongyue; MAO Zhezhe
Handan Central Hospital,Hebei Handan 056002,China.
Keywords:
non-small cell lung cancer; prognosis; postoperative; column graph prediction model
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2024.10.010
Abstract:
Objective：To analyze the factors influencing poor postoperative prognosis in patients with non-small cell lung cancer (NSCLC) and to construct a line graph prediction model.Methods:Clinical data of 168 patients with non-small cell lung cancer who underwent surgery at our hospital from January 2018 to February 2020 were collected.They were divided into good prognosis group (n=76) and poor prognosis group (n=92) according to the 3-year postoperative follow-up.The optimal cut-off values of each factor were analyzed by subject operating characteristic (ROC) curves.The logistic multiple regression model was used to analyse the independent risk factors for poor postoperative prognosis in non-small cell lung cancer patients and to construct a nomogram prediction model,and the internal validation and predictive efficacy of the nomogram model were assessed by calibration curves and decision curves,respectively.Results:The age,proportion of males,proportion of smoking history,proportion of adenocarcinoma,proportion of mediastinal lymph node metastasis,proportion of lesion diameter >3 cm,proportion of TNM stage III/IV,proportion of poor differentiation,and levels of CEA and CA125 in the poor prognosis group were higher than those in the good prognosis group,and the difference was statistically significant (P＜0.05).The results of ROC curve analysis showed that the optimal cut-off values for age,CEA,and CA125 were 65 years,10.49 ng/mL,and 40.36 ng/mL,respectively.Logistic multiple regression model results showed that the history of smoking (yes),TNM stage (stage III/IV),lesion size (diameter >3 cm),degree of differentiation (poor differentiation),mediastinal lymph node metastasis (yes),CEA (>10.49 ng/mL),CA125 (>40.36 ng/mL) were independent risk factors for poor postoperative prognosis in non-small cell lung cancer patients.The internal validation results showed that the C-index of the column graph model for predicting poor postoperative prognosis in non-small cell lung cancer patients was 0.871 (95%CI:0.752~0.963).The agreement between the observed and predicted values was good.The threshold for the column-line diagram model was >0.13,and the column-line diagram model provided all net clinical benefits over smoking history,TNM stage,lesion size,degree of differentiation,mediastinal lymph node metastasis,CEA,and CA125.Conclusion:In this study,the column-line diagram model constructed on the basis of smoking history,TNM staging,lesion size,degree of differentiation,mediastinal lymph node metastasis,CEA,and CA125 has good predictive value for poor postoperative prognosis in patients with non-small cell lung cancer,which can provide a basis for clinical improvement of postoperative prognosis in non-small cell lung cancer.

References:

［1］ 吴方雨,陈卫东,夏盼盼,等.埃克替尼对比吉非替尼治疗EGFR突变型晚期NSCLC的临床观察［J］.中国药房,2023,34(10):1228-1232. WU FY,CHEN WD,XIA PP,et al.Clinical observation of icotinib versus gefitinib in the treatment of EGFR-mutated advanced non-small cell lung cancer［J］.China Pharmacy,2023,34(10):1228-1232.
［2］ 夏瑶,司毛燕,朱慎钰,等.ctDNA的研究现状及在肺癌诊疗中的研究进展［J］.中国医学创新,2023,20(14):184-188. XIA Y,SI MY,ZHU SY,et al.Research status of ctDNA and research progress in diagnosis and treatment of lung cancer［J］.Medical Innovation of China,2023,20(14):184-188.
［3］ BALACHANDRAN VP,GONEN M,SMITH JJ,et al.Nomograms in oncology:more than meets the eye［J］.Lancet Oncol,2015,16(4):173-180.
［4］ 方宁宁,袁轶群.GPR120、SCC-Ag、PD-1在非小细胞肺癌中的表达及其与临床特征、预后的关系［J］.中外医学研究,2023,21(10):72-77. FANG NN,YUAN YQ.Expression of GPR120,SCC-Ag and PD-1 in non-small cell lung cancer and the relationship with clinical characteristics and prognosis［J］.Chinese and Foreign Medical Research,2023,21(10):72-77.
［5］ 季学波,黄正军,景永,等.非小细胞肺癌应用胸腔镜肺癌手术治疗的临床疗效观察［J］.中国卫生标准管理,2023,14(05):95-98. JI XB,HUANG ZJ,JING Y,et al.Clinical efficacy of thoracoscopic lung cancer in the treatment of non-small cell lung cancer［J］.China Health Standard Management,2023,14(05):95-98.
［6］ ZHANG J,PAN Z,ZHAO F,et al.Development and validation of a nomogram containing the prognostic determinants of chondrosarcoma based on the surveillance,epidemiology,and end results database［J］.Int J Clin Oncol,2019,24(11):1459-1467.
［7］ 胡硕红,郑学彬,李富杰.老年人根面龋相关危险因素分析及列线图预测模型构建［J］.临床口腔医学杂志,2022,38(12):721-724. HU SH,ZHENG XB,LI FJ.Analysis of risk factors related to root caries in the elderly and construction of a nomogram prediction model［J］.Journal of Clinical Stomatology,2022,38(12):721-724.
［8］ 黄晓，邵旻婧，王嘉琪，等.预测年轻乳腺癌患者生存率列线图的建立和验证［J］.现代肿瘤医学，2022，30（17）：3120-3126. HUANG X,SHAO MJ,WANG JQ,et al.Development and validation of nomogram for predicting survival outcomes in young breast cancer patients［J］.Modern Oncology,2022，30（17）：3120-3126.
［9］ 齐泽迪，屈一晨，张明达，等.基于SEER数据库低级别胶质瘤预后列线图的构建［J］.现代肿瘤医学，2023,31（11）：2031-2036. QI ZD,QU YC,ZHANG MD,et al.Construction of prognostic nomogram for low-grade glioma based on SEER database［J］.Modern Oncology,2023,31（11）：2031-2036.
［10］ 史良恬,晏军,孟玉凤,等.补肺活血胶囊对慢性阻塞性肺疾病模型大鼠气道重塑的干预作用及机制研究［J］.安徽中医药大学学报,2022,41(01):59-65. SHI LT,YAN J,MENG YF,et al.Intervention effect of Bufei Huoxue Capsule on airway remodeling in a rat model of chronic obstructive pulmonary disease and its mechanism［J］.Journal of Anhui University of Chinese Medicine,2022,41(01):59-65.
［11］ 花宝金,庞博,朴炳奎.中医药防治肺癌的优势与策略［J］.北京中医药,2022,41(05):472-475. HUA BJ,PANG B,PIAO BK.Advantages and strategies of TCM in preventing and treating lung cancer［J］.Beijing Journal of Traditional Chinese Medicine,2022,41(05):472-475.
［12］ 杨冉,韩金利,侯建彬,等.非小细胞肺癌手术前后长链非编码RNA水平变化及其与预后的关系［J］.实用医院临床杂志,2021,18(06):75-78. YANG R,HAN JL,HOU JB,et al.Changes in LncRNAs levels before and after NSCLC surgery and their relationship with prognosis［J］.Practical Journal of Clinical Medicine,2021,18(06):75-78.
［13］ SHIMADA Y,SAJI H,YOSHIDA K,et al.Pathological vascular invasion and tumor differentiation predict cancer recurrence in stage Ia non-small-cell lung cancer after complete surgical resection［J］.J Thorac Oncol,2012,7(8):1263-1270.
［14］ 程越.肿瘤标志物在肺癌诊断、病理分型和临床分期中的价值探析［J］.中国处方药,2016,14(12):155-156. CHENG Y.Exploring the value of tumour markers in the diagnosis,pathological staging and clinical staging of lung cancer［J］.Journal of China Prescription Drug,2016,14(12):155-156.
［15］ HOLDENRIEDER S,WEHNL B,HETTWER K,et al.Carcinoembryonic antigen and cytokeratin-19 fragments for assessment of therapy response in non-small cell lung cancer:a systematic review and meta-analysis［J］.Br J Cancer,2017,116(8):1037-1045.
［16］ YANG W,LUO Y,HU S,et al.Value of combined detection of serum carcino-embryonic antigen,carbohydrate antigen 19-9 and cyclooxygenase-2 in the diagnosis of colorectal cancer［J］.Oncol Lett,2018,16(2):1551-1556.
［17］ KATAOKA Y,HIRANO K,NARABAYASHI T,et al.Carcinoembryonic antigen as a predictive biomarker of response to nivolumab in non-small cell lung cancer［J］.Anticancer Res,2018,38(1):559-563.
［18］ 吕剑.血清CEA、CA125、CA19-9联合检测在肺癌患者治疗中的临床价值［J］.国际检验医学杂志,2018,39(11):1322-1325,1328. LYU J.The value of combined detection of serum CEA,CA125 and CA19-9 in the treatment of lung cancer patients［J］.International Journal of Laboratory Medicine,2018,39(11):1322-1325,1328.
［19］ 解玉卓，黄伟，赵涵，等.血清CA125、D-二聚体水平与非小细胞肺癌关系研究进展［J］.现代肿瘤医学，2019,27（7）:1262-1265. XIE YZ,HUANG W,ZHAO H,et al.Research progression on the relationship between serum CA125 and D-dimer level and non-small cell lung cancer［J］.Modern Oncology,2019,27（7）:1262-1265.

Memo

Memo:
河北省医学科学研究课题计划项目(编号：20220552)
Last Update: 1900-01-01